27 min listen
A Small Molecule Cancer Drug That Promotes an Adaptive Immune Response
FromThe Bio Report
ratings:
Length:
30 minutes
Released:
Feb 25, 2021
Format:
Podcast episode
Description
Phosplatin Therapeutics is developing a class of small molecule cancer therapies designed to avoid the problems of drug resistance and toxicity associated with chemotherapies. The company’s lead experimental therapy is a first-in-class small molecule that promotes immunogenic cell death, a type of cell death that elicits an immune response. We spoke to Matthew Price, co-founder, executive vice president, and chief operating officer of Phosplatin, about the company’s lead therapy, its multiple mechanisms of action, and why it may have benefit in a broad range of cancers.
Released:
Feb 25, 2021
Format:
Podcast episode
Titles in the series (100)
Remembering Industry Pioneer Ron Cape by The Bio Report